Investing.com -- Morgan Stanley downgraded Enfusion Inc (NYSE:ENFN) stock to "Equal-weight" from "Overweight" following Clearwater Analytics' proposed $1.5 billion acquisition at $11.25 per share.
With the bid accelerating value realization, Morgan Stanley (NYSE:MS) raised its price target by 25 cents to $11.25, in line with the offer price.
“One of the central tenets of our historical Overweight thesis was predicated on untapped strategic value that resulted in minimal absolute downside and an asymmetric risk-reward. With CWAN's proposed acquisition of Enfusion at $11.25, strategic value has been unlocked and we step to the sidelines,” Morgan Stanley analyst wrote.
The offer represents a 13% premium to Enfusion's most recent closing price and a 32% premium to its September 2024 levels.
Morgan Stanley noted that the deal unlocks strategic value for shareholders and addresses longstanding challenges such as limited stock float and a high concentration of startup hedge fund clients.
MS added it had long held the view on Enfusion as a strategically valuable asset, burdened by limited public float.
Related Articles
MS cuts rating on Enfusion stock after Clearwater’s acquisition bid
Biden administration to revoke Cuba's terrorism sponsor designation
Apple, Amazon fight off $600 million UK lawsuit over alleged 'collusion'
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.